MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1549-1555

  Cai, Jingli ^a,b   Xu, Lubai ^b   Cai, Zhenzhai ^c   Wang, Jisheng ^b   Zhou, Bing ^b   Hu, Hai ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Department of General Surgery ^*  (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Gallbladder cancer; MicroRNA 146b 5p

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 146B 5P; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MIRN146 MICRORNA, HUMAN;

ADULT; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CANCER STAGING; CARCINOGENICITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE CONTROL; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MIDDLE AGED; MTT ASSAY; PROTEIN TARGETING; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA; GALLBLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84926669475     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3461     Document Type: Article

References (24)

1. Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist 15: 168-181, 2010.
2. Hueman MT, Vollmer CM Jr and Pawlik TM: Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16: 2101-2115, 2009.
3. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med 341: 1368-1378, 1999.
4. Zhang LQ, Zhang XD, Xu J, et al: Potential therapeutic targets for the primary gallbladder carcinoma: estrogen receptors. Asian Pac J Cancer Prev 14: 2185-2190, 2013.
5. McNamara MG, Metran-Nascente C and Knox JJ: State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 25: 425-431, 2013.
6. Farh KK, Grimson A, Jan C, et al: The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817-1821, 2005.
7. Wu WK, Lee CW, Cho CH, et al: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5771, 2010.
8. Peng HH, Zhang YD, Gong LS, Liu WD and Zhang Y: Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. Onco Targets Ther 6: 1625-1630, 2013.
9. Kono H, Nakamura M, Ohtsuka T, et al: High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep 30: 17-24, 2013.
10. Chang Y, Liu C, Yang J, et al: MiR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 59: 518-527, 2013.
11. Rasheed BK, Fuller GN, Friedman AH, Bigner DD and Bigner SH: Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer 5: 75-82, 1992.
12. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279-1283, 2009.
13. Lin F, Wang X, Jie Z, et al: Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ Sci Technolog Med Sci 31: 509-514, 2011.
14. Datta J, Majumder S, Kutay H, et al: Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 67: 2736-2746, 2007.
15. Nasser MW, Datta J, Nuovo G, et al: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405, 2008.
16. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 28: 1024-1030, 2010.
17. Harder J, Waiz O, Otto F, et al: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15: 4511-4517, 2009.
18. Harris RC, Chung E and Coffey RJ: EGF receptor ligands. Exp Cell Res 284: 2-13, 2003.
19. Ménard S, Casalini P, Campiglio M, Pupa SM and Tagliabue E: Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61: 2965-2978, 2004.
20. Aaronson SA: Growth factors and cancer. Science 254: 1146-1153, 1991.
21. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
22. Harder J, Waiz O, Otto F, et al: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15: 4511-4517, 2009.
23. Pignochino Y, Sarotto I, Peraldo-Neia C, et al: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10: 631, 2010.
24. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647, 2008.